Loading...
Market
What will be the outcome of the $1.7 billion contingent milestone payments in the Merck-EyeBio deal by 2025?
2
Resolution / Starting Odds
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
Merck's financial disclosures or press releases
Story
Merck to Acquire Kate Bingham-Backed EyeBio for Up to $3 Billion
May 29, 2024, 10:43 AM
Merck & Co., known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire the Kate Bingham-backed ophthalmology-focused biotechnology company EyeBio for up to $3 billion. The deal includes an upfront payment of $1.3 billion, with an additional $1.7 billion contingent on milestone achievements. EyeBio, a clinical-stage company, is developing treatments for common eye diseases, including the Restoret drug for retinal diseases, and will enter late-stage clinical testing in the coming months. This acquisition marks Merck's continued efforts to expand its presence in the ophthalmology sector.
View original story
Similar markets
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Under $200 million • 25%
Between $200 million and $500 million • 25%
Between $500 million and $800 million • 25%
Over $800 million • 25%
Less than 10% • 33%
10% to 20% • 33%
More than 20% • 33%
Less than £5 billion • 25%
£5 billion to £10 billion • 25%
£10 billion to £15 billion • 25%
More than £15 billion • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened financial performance • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Fully integrated by mid-2025 • 25%
Fully integrated by end of 2025 • 25%
Integration delayed beyond 2025 • 25%
Integration halted or reversed • 25%